Circulating tumor DNA guided extra treatment for early triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether using a blood test to detect leftover cancer DNA after initial treatment can help doctors decide if extra therapy is needed for people with early triple-negative breast cancer. It aims to improve outcomes for those with remaining disease after neoadjuvant therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have stage II or III breast cancer, but not occult, inflammatory, or metaplastic types.
- You must have triple-negative breast cancer, which means your tumor has low or no estrogen and progesterone receptors, and HER2 is negative.
- You must have had neoadjuvant (before surgery) therapy and still have some cancer remaining after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether checking DNA from your blood (circulating tumor DNA) can help doctors choose the best neoadjuvant (pre-surgery) treatment for HER2-positive or triple-negative breast cancer. It aims to personalize therapy based on how your tumor responds.
This trial uses a blood test called ctDNA to see who is at higher risk after surgery and standard chemotherapy for triple-negative breast cancer. If your ctDNA test is positive, you may receive an extra “boost” treatment to help reduce the chance the cancer returns.
This trial uses a simple blood test to look for leftover cancer DNA in people with triple-negative breast cancer who still have disease after chemotherapy and surgery. It aims to catch any early signs of the cancer coming back.
This study uses a computer (AI) to read results from blood tests to look for signs of remaining triple-negative breast cancer, before and/or after surgery. It may help doctors better detect residual tumor and guide follow-up care.
This study is testing a research tool that may help doctors choose the best treatment for people with advanced triple-negative breast cancer. You will have a biopsy and blood draw to help see how the tool works.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.